Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis
Authors' conclusion
This study confirmed the presence of several proteins in the urine of JDM patients that were previously found to be elevated in the blood of myositis patients and identified novel candidate biomarkers that require validation.
Study context
- Population
- JDM patients and healthy controls; first morning void urine samples
- Participants
- 20 vs 21
- Exposure
- JDM vs healthy controls
- JDMn = 20
- Healthy controlsn = 21reference
- Outcome
- Urine biomarkers with significantly altered levels in JDM
Methodological detailsurine proteome profiling, multiplexing tandem mass tag, liquid chromatography-tandem mass spectrometry, ELISA validation
- Urine proteome profiling
- Multiplexing tandem mass tag
- Liquid chromatography-tandem mass spectrometry
- ELISA validation
Main finding
As reported in the abstract
Differentially altered urine proteins
Proteins detected
2348
Proteins quantified across all samples
275
Cathepsin D and galectin-3 binding protein significantly increased in urine of JDM patients
adjusted P < 0.05
Observational data: associations, not effects.
Further findings
Correlation of cathepsin D with clinical measures
- Cathepsin D vs Myositis Damage Index (positive correlation), r
- 0.57, P < 0.05
- Cathepsin D vs Childhood Myositis Assessment Scale (negative correlation), r
- −0.54, P < 0.05
Original publication
Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis. Rheumatology (Oxford). Published 20 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →